Kevin Pantalone, DO
Endocrinology, Diabetes & Metabolism · Cleveland, OHNPI 1922293547
Payments from drug & device makers
Across 2,581 payments — averaging $1538.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1.9M
- Novo Nordisk AS$504K
- Corcept Therapeutics$459K
- Eli Lilly$388K
- AstraZeneca$315K
- Merck$246K
- plus $151K from 13 others
Across 7 payments — averaging $679.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$750
What the payments were for
- Consulting fees$200,66317%
- Speaking & faculty fees$834,51269%
- Travel & lodging$152,20613%
- Food & beverage$28,2902%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 269 | $1,909,930 |
| Novo Nordisk AS | 1,088 | $504,185 |
| Corcept Therapeutics | 462 | $459,088 |
| Eli Lilly | 131 | $387,655 |
| AstraZeneca | 316 | $314,625 |
| Merck | 57 | $245,905 |
| Bayer | 133 | $96,370 |
| Sanofi-aventis U.S. LLC | 20 | $22,267 |
| Boehringer Ingelheim | 18 | $17,668 |
| Lilly USA, LLC | 60 | $9,464 |
| Mannkind Corporation | 6 | $4,429 |
| Insulet Corporation | 5 | $114 |
| Xeris Pharmaceuticals, Inc. | 5 | $87 |
| Dexcom, Inc. | 4 | $72 |
| Recordati_rare_diseases_inc. | 3 | $51 |
| Johnson & Johnson | 1 | $35 |
| Medtronic | 1 | $34 |
| Sequel Med Tech, LLC | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,972,021 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 36 | $2,647,868 |
| OzempicSemaglutide | 275 | $499,680 |
| MounjaroTirzepatide | 112 | $142,559 |
| FarxigaDapagliflozin Propanediol | 99 | $125,977 |
| TrulicityDulaglutide | 80 | $124,136 |
| JardianceEmpagliflozin | 77 | $119,738 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 54 | $45,949 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $38,282 |
| JanuviaSitagliptin Phosphate | 13 | $20,574 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $18,548 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 17 | $13,282 |
| RybelsusSemaglutide | 12 | $11,812 |
| KerendiaFinerenone | 14 | $10,704 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $9,675 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 28 | $7,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $459,088 | $2,647,86836 claims |
| Novo NordiskOzempic, Rybelsus | $1,909,930 | $511,492287 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $9,464 | $272,258220 claims |
| AstraZenecaFarxiga | $314,625 | $125,97799 claims |
| Boehringer IngelheimJardiance | $17,668 | $119,73877 claims |
| MerckJanuvia | $245,905 | $20,57413 claims |
| BayerKerendia | $96,370 | $10,70414 claims |
| Sanofi-aventis U.S. LLCLantus | $22,267 | $1,68312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Cleveland
- Bartolome BurgueraCleveland$3.1M
- Allan KennedyCleveland$277K
- Maria LansangCleveland$208K
- Christian NasrCleveland$205K
- Sangeeta KashyapCleveland$158K
- Amir HamrahianCleveland$139K
- Adi MehtaCleveland$120K
- Betul HatipogluCleveland$82K
- Willy Valencia RodrigoCleveland$63K
- Robert ZimmermanCleveland$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.